Financial results for the half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
EP Biocomposites Ltd reported a sharp slowdown in H1 FY26 (Apr–Sep 2025) with revenue from operations falling to Rs. 407.48 lakhs from Rs. 440.49 lakhs in H1 FY25, a decline of about 7.5% year-on-year. Profit after tax nearly halved to Rs. 9.04 lakhs versus Rs. 20.55 lakhs in the same period last year, while profit before tax dropped to Rs. 12.07 lakhs from Rs. 31.07 lakhs. The company burned cash in operations, with net cash used in operating activities at -Rs. 130.64 lakhs compared to a smaller outflow last year, and cash on hand fell to Rs. 87.83 lakhs from Rs. 161.67 lakhs. Total expenses remained broadly flat at Rs. 402.64 lakhs, indicating margin pressure rather than a cost-driven squeeze. The statutory auditor issued an unqualified limited review report.
Shareholders should note a clear deterioration in profitability and cash generation despite stable revenue scale, suggesting margin compression and working capital strain. The negative operating cash flow and halving of profits could weigh on the stock in the near term.